Upgrade to SI Premium - Free Trial

Immunovant (IMVT) Reiterated at Overweight by Cantor Fitzgerald on Model Update

August 25, 2026 7:40 AM
Cantor Fitzgerald analyst Prakhar Agrawal reiterated an Overweight rating on Immunovant (NASDAQ ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments